Title: | A loss-of-function variant in ALOX15 protects against nasal polyps and chronic rhinosinusitis |
Journal: | Nature Genetics |
Published: | 14 Jan 2019 |
Pubmed: | https://pubmed.ncbi.nlm.nih.gov/30643255/ |
DOI: | https://doi.org/10.1038/s41588-018-0314-6 |
Title: | A loss-of-function variant in ALOX15 protects against nasal polyps and chronic rhinosinusitis |
Journal: | Nature Genetics |
Published: | 14 Jan 2019 |
Pubmed: | https://pubmed.ncbi.nlm.nih.gov/30643255/ |
DOI: | https://doi.org/10.1038/s41588-018-0314-6 |
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Nasal polyps (NP) are lesions on the nasal and paranasal sinus mucosa and are a risk factor for chronic rhinosinusitis (CRS). We performed genome-wide association studies on NP and CRS in Iceland and the UK (using UK Biobank data) with 4,366 NP cases, 5,608 CRS cases, and >700,000 controls. We found 10 markers associated with NP and 2 with CRS. We also tested 210 markers reported to associate with eosinophil count, yielding 17 additional NP associations. Of the 27 NP signals, 7 associate with CRS and 13 with asthma. Most notably, a missense variant in ALOX15 that causes a p.Thr560Met alteration in arachidonate 15-lipoxygenase (15-LO) confers large genome-wide significant protection against NP (P = 8.0 × 10−27, odds ratio = 0.32; 95% confidence interval = 0.26, 0.39) and CRS (P = 1.1 × 10−8, odds ratio = 0.64; 95% confidence interval = 0.55, 0.75). p.Thr560Met, carried by around 1 in 20 Europeans, was previously shown to cause near total loss of 15-LO enzymatic activity. Our findings identify 15-LO as a potential target for therapeutic intervention in NP and CRS.</p>
Enabling scientific discoveries that improve human health